Section Arrow
PRLD.NASDAQ
- Prelude Therapeutics
Quotes are at least 15-min delayed:2024/06/13 00:22 EDT
Last
 4.01
-0.01 (-0.25%)
Day High 
4.44 
Prev. Close
4.02 
1-M High
4.42 
Volume 
69.57K 
Bid
4.02
Ask
4.05
Day Low
3.89 
Open
4.19 
1-M Low
3.32 
Market Cap 
220.82M 
Currency USD 
P/E -- 
%Yield
10-SMA 3.76 
20-SMA 3.89 
50-SMA 4.11 
52-W High 5.83 
52-W Low 1.66 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-1.86/-1.83
Enterprise Value
236.22M
Balance Sheet
Book Value Per Share
3.84
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
0
Operating Revenue Per Share
--
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
LGVNLongeveron1.81+0.99+120.73%-- 
DNAGinkgo Bioworks Holdings0.5076-0.0087-1.69%-- 
NVAXNovavax15.85-0.875-5.23%-- 
GERNGeron Corp5.08-0.01-0.20%-- 
RNAAvidity Biosciences38.34+9.42+32.57%-- 
Quotes are at least 15-min delayed:2024/06/13 00:22 EDT
Industry overview quotes are at least 15 minutes delayed
Business Description
Prelude Therapeutics Incorp is a clinical-stage precision oncology company focused on discovering and developing small molecule therapies optimized to target the key driver mechanisms in cancers with high unmet needs. The company's pipeline includes four candidates currently in clinical development: PRT1419, a potent, selective inhibitor of MCL1; PRT2527, a potent and selective CDK9 inhibitor, PRT3645, a next-generation CDK4/6 inhibitor, and PRT3789 a first-in-class SMARCA2/BRM protein degrader.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.